Now showing items 1-4 of 4

    • The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase 

      Cox, TR; Rumney, RMH; Schoof, EM; Perryman, L; Hoye, AM; Agrawal, A; Bird, D; Ab Latif, N; Forrest, H; Evans, HR; Huggins, ID; Lang, G; Linding, R; Gartland, A; Erler, JT (NATURE PUBLISHING GROUP, 2015-06-04)
      Tumour metastasis is a complex process involving reciprocal interplay between cancer cells and host stroma at both primary and secondary sites, and is strongly influenced by microenvironmental factors such as hypoxia(1). ...
    • Network-based drugs and biomarkers. 

      Erler, JT; Linding, R (2010-01)
      The structure and dynamics of protein signalling networks governs cell decision processes and the formation of tissue boundaries. Complex diseases such as cancer and diabetes are diseases of such networks. Therefore ...
    • The rationale for targeting the LOX family in cancer 

      Barker, HE; Cox, TR; Erler, JT (NATURE PUBLISHING GROUP, 2012-08)
      The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the ...
    • Tumor-Secreted LOXL2 Activates Fibroblasts through FAK Signaling 

      Barker, HE; Bird, D; Lang, G; Erler, JT (AMER ASSOC CANCER RESEARCH, 2013-11)
      Cancer-associated fibroblasts enhance cancer progression when activated by tumor cells through mechanisms not yet fully understood. Blocking mammary tumor cell-derived lysyl oxidase-like 2 (LOXL2) significantly inhibited ...